Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPTLC1 | O15269 | 1/20 | 0.67 |
| ▸ | SPTLC2 | O15270 | 1/20 | 0.67 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | MME | P08473 | 10/20 | 0.43 |
| ▸ | ACE | P12821 | 5/20 | 0.43 |
| ▸ | CPA1 | P15085 | 2/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.43 |
| ▸ | MMEL1 | Q495T6 | 7/20 | 0.42 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6805644 | 0.93 | SPTLC1 (0.72) | SPTLC1SPTLC2FAAHMMEACE | |
| SCHEMBL6804868 | 0.92 | SPTLC1 (0.75) | SPTLC1SPTLC2FAAHMMEACE | |
| SCHEMBL14190668 | 0.92 | SPTLC1 (0.75) | SPTLC1SPTLC2FAAHMMEACE | |
| SCHEMBL14190672 | 0.92 | SPTLC1 (0.75) | SPTLC1SPTLC2FAAHMMEACE | |
| SCHEMBL14190630 | 0.92 | SPTLC1 (0.68) | SPTLC1SPTLC2FAAHMMEACE | |
| SCHEMBL14190635 | 0.91 | SPTLC1 (0.67) | SPTLC1SPTLC2FAAHMMEACE | |
| SCHEMBL14190616 | 0.91 | SPTLC1 (0.75) | SPTLC1SPTLC2FAAHMMEACE | |
| SCHEMBL6805680 | 0.91 | SPTLC1 (0.75) | SPTLC1SPTLC2FAAHMMEACE | |
| SCHEMBL6748251 | 0.90 | SPTLC1 (0.70) | SPTLC1SPTLC2FAAHMMEACE | |
| SCHEMBL6748266 | 0.90 | SPTLC1 (0.70) | SPTLC1SPTLC2FAAHMMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183005-B1 | Pharmaceutical agents for treating HCV infections | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183005-B1 | Pharmaceutical agents for treating HCV infections | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20110160252-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OR PREVENTION OF HBV INFECTION | PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110160252-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OR PREVENTION OF HBV INFECTION | PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY (JP) | 2011-06-30 | — | — | US | disclosed |
| US-7378446-B2 | Compound having anti-HCV activity and process for producing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-27 | — | — | US | disclosed |
| US-7378446-B2 | Compound having anti-HCV activity and process for producing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160252-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OR PREVENTION OF HBV INFECTION | IFNG, HDGF, HAVCR2 | SPTLC1 4049/4885SPTLC2 4400/4885FAAH 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.